Neuberger Berman Group
ACER

Neuberger Berman Group’s Acer Therapeutics Inc ACER Stock Holding History

Neuberger Berman Group’s Portfolio ACER Stock Details ACER Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-20,000
Closed -$385K – 1771
2018
Q1 		$385K Buy
+20,000
New +$367K ﹤0.01% 1409

Other funds holding ACER

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Neuberger Berman Group's ACER Position: Q2 2018 in Review

Neuberger Berman Group sold out of Acer Therapeutics Inc (ACER) in Q2 2018, closing a stake of 20,000 shares — an estimated $385K sold.

Neuberger Berman Group first reported a position in ACER in Q1 2018 and held it in 1 quarter. The position peaked at $385K in Q1 2018. 17 funds tracked by Wall St. Rank hold ACER as of Q2 2018.

  • Neuberger Berman Group reported no remaining Acer Therapeutics Inc position as of Q2 2018 after selling out during the quarter.
  • Neuberger Berman Group sold 20,000 Acer Therapeutics Inc shares in Q2 2018, an estimated $385K.
  • Neuberger Berman Group first reported a position in Acer Therapeutics Inc in Q1 2018 and held it in 1 quarter.
  • Neuberger Berman Group's Acer Therapeutics Inc position peaked at $385K in Q1 2018.
  • 17 funds tracked by Wall St. Rank held Acer Therapeutics Inc as of Q2 2018.

Based on Neuberger Berman Group's 13F filing for Q2 2018, filed 13 Aug 2018.